Kornimate/medical-research-clean huggingface dataset:
the effectiveness of acupuncture therapy on pain in parkinson's disease

Conditions: Parkinson Disease; Pain, Neck

Summary: parkinson's disease (pd) is a chronic, progressive, degenerative movement disorder that is characterized by motor and nonmotor symptoms and its incidence increases with age. it has been reported that 40-90% of patients have pain symptoms in pd. pain can be the result of motor fluctuations, dystonic muscle contractions, deep visceral pain, and musculoskeletal pain.

parkinson's disease (pd) is a chronic, progressive, degenerative movement disorder that is characterized by motor and nonmotor symptoms and its incidence increases with age. it is the second most common neurodegenerative disease after alzheimer's.bradykinesia, which is characterized by rigidity, resting tremor, postural instability, gait disturbance and progressive decrease in the speed and amplitude of repetitive movements throughout the course of the disease, are the main cardinal motor findings.sensory dysfunction such as non-motor findings in pd, disruption in the sleep-wake cycle, neuropsychiatric findings such as dementia, confusion, hallucinations, delirium, depression, gastrointestinal dysfunction, autonomic nervous system disorders such as bladder dysfunction, orthostatic hypotension, and pain perception may develop.although dopaminergic therapies in pd are the gold standard in the treatment of disorders such as bradykinesia, rigidity and tremor, adequate response cannot be obtained in the treatment of non-motor symptoms. for this reason, rehabilitative applications, especially pain symptom, and complementary medicine methods are very important.it has been reported that 40-90% of patients have pain symptoms in pd. pain can be the result of motor fluctuations, dystonic muscle contractions, deep visceral pain, and musculoskeletal pain. acupuncture and dry needling therapy have been used clinically for a long time as pain relievers such as migraine pain, low back pain, chronic pain and cancer pain. on the other hand, there are very limited and very limited number of studies on the efficacy of dry needle therapy applied to acupuncture points in pain control in pd.in this study, our aim is to investigate the effectiveness of dry needling treatment applied to acupuncture points in neck pain due to ph on musculoskeletal pains.

Eligibility criteria:
inclusion criteria: * being parkinson's disease * age 45-75 * have a pain due to parkinson's disease exclusion criteria: * presence of advanced dementia or mental disability * pain due to ınflammatory conditions * using anticoagulant therapy
blood samples to identify biomarkers in patients treated with cyclophosphamide after donor stem cell transplant

Conditions: Allogeneic Hematopoietic Stem Cell Transplant Recipient; Donor; Malignant Neoplasm

Summary: this trial uses blood samples to understand how patients' bodies process and respond to a drug called cyclophosphamide given after a donor stem cell transplant. identifying biomarkers (molecules that can indicate normal or abnormal processes) may help researchers develop a blood test that can be used to predict how well patients will process and respond to cyclophosphamide.

"ancillary-correlative" study type primary objectives: i. to determine whether endogenous metabolomics compounds obtained before cyclophosphamide administration can predict the ratio of 4hydroxycyclophosphamide to cyclophosphamide area under the curve (4hcy/cy auc). ii. to evaluate mathematic models of cy and mycophenolic acid (mpa) pharmacokinetics and develop mathematic models including these pharmacokinetics, -omics data and clinical outcomes. secondary objectives: i. to assess if recipients' metabolomics and pharmacokinetics (e.g., cy and its metabolites aucs) are associated with acute graft versus host disease (gvhd) and other clinical outcomes. ii. to assess the association of the intestinal microbiome with the plasma metabolome, acute gvhd and other clinical outcomes. iii. to obtain donor blood samples at one time pre-transplant and assess if donors' metabolomics are associated with acute gvhd and other clinical outcomes. exploratory objective: i. donor and recipient germline deoxyribonucleic acid (dna) isolation and genomic analysis. outline: participants are assigned to 1 of 2 arms. arm i (patients receiving a haploidentical transplant): patients undergo collection of blood prior to transplant, on day 0, days 3-7, day 14, and day 21. patients also undergo collection of saliva prior to transplant and collection of stool prior to and post-transplant. donors undergo collection of blood and saliva within 8 weeks prior to donation.

Eligibility criteria:
inclusion criteria: * scheduled to undergo allogeneic hematopoietic cell transplant (hct) with a haploidentical donor. * allogeneic hct scheduled to treat any underlying disease. patients with nonmalignant diseases or cancer are eligible * scheduled to receive post-transplant cyclophosphamide (any dose, any number of doses, any dosing frequency) as part of their post-graft immunosuppression or gvhd prophylaxis. patients enrolled on treatment protocols that include post transplant cyclophosphamide (ptcy) but do not include mycophenolate mofetil (mmf) or tacrolimus can participate * willingness to: * provide blood * permit medical record review
pseudoaneurysm of the greater palatine artery following autogenous connective tissue gingival graft : a case series

Conditions: Pseudoaneurysm

Summary: gingival recession is defined as the apical migration of the gingival margin from the amelocemental junction. this condition may be associated with symptoms such as tooth hypersensitivity, root decay, and cosmetic complaints from patients. many treatments have been used to treat gingival recession and the gold standard is the autogenous connective tissue gingival graft because of its predictability. this type of gingival graft is performed by harvesting connective tissue from patients' hard palate. periodontists and general dentists frequently perform these gingival grafts. occasionally, some patients develop postoperative complications that need to be addressed in an hospital setting. an uncommon but concerning complication of an autogenous connective tissue gingival graft is a donor site pseudoaneurysm of the greater palatine artery. no description of this complication following a gingival graft has been identified in the current literature. one case report mentioned that pseudoaneurysm of the greater palatine artery looks like a pulsatile nodule associated or not with pain on palpation. from the experience of the investigators, patients may consult an hospital setting having a complaint of major oral bleeding. local hemostatic agents can palliate this type of bleeding, but angiographic embolization is often required. several cases were treated in the investigators' hospital. thus, the investigators believe it is relevant to share this experience with the scientific community. the primary objective of this case series is to inform dental professionals of the existence and the management of postoperative pseudoaneurysm of the greater palatine artery following autogenous gingival graft. the secondary objective is to find potential solutions to minimize the incidence of this morbid complication.


Eligibility criteria:
inclusion criteria: * population : patients having a diagnostic of pseudoaneurysm of the greater palatine artery who had an autogenous connective tissue gingival graft * intervention : patients treated with local hemostatic agents or by angiographic embolization * comparison : none exclusion criteria: * missing data in patients' chart precluding complete data extraction

Keywords: gingival graft pseudoaneurysm postoperative complication gingival recession treatment palatine mass palatine bleeding
effect of the use of a visual feedback device in rcp trainings

Conditions: Simulation Training

Summary: to verify the efficacy of manikins with feedback in the training of physicians and nurses in the courses of advanced cardiac life support (acls) authorized by the american heart association (aha) when compared to the traditional training form.

introduction: the cardiopulmonary arrest (crp) is the largest medical emergency, training is fundamental for a good performance in cardiopulmonary resuscitation (cpr). in a realistic simulation scenario, the results tend to improve with the use of feedback manikins that evaluate the quality parameters in cpr and show in real time what the rescuer needs to improve in order to be successful in training and increase the probability of success in future real care. objective: to verify the efficacy of the manikins with feedback in the training of physicians and nurses in the courses of advanced cardiac life support (acls) authorized by the american heart association (aha). methods: comparison of cpr performance of acls students. the intervention group will be submitted to the real-time feedback of the manikins, the control group will receive feedback from the instructor. statistical analysis will consist of inter-group comparisons and will cover mean, standard deviation, and parametric tests such as student's t test. the results will be related to the characteristics of the sample, including anthropometric profile, profession, training time, practice area, previous training with a focus on cpr and physical exercise practice.

Eligibility criteria:
inclusion criteria: be an acls student and sign the tcle. - exclusion criteria: refusing to sign the tcle -

Keywords: cardiopulmonary ressuscitattion education medical continuing emergency medical services simulation training feedback dummy
advance crt - d: antitachycardia pacing (atp) delivery for painless implantable cardioverter defibrillator (icd) therapy

Conditions: Tachycardia, Ventricular; Ventricular Fibrillation

Summary: to compare the efficacy of rv and biv atp for the termination of ventricular arrhythmias in patients who are candidates to a cardiac resynchronisation therapy (crt) and have a class i or iia indication for icd implantation. the hypothesis of delivering atp from different sites (rv or biv) has never been evaluated in a prospective, controlled and randomized study.

main objective: compare efficacy of atp therapy (burst, 8 pulses, 88 %, 1 sequence) to terminate all types of ventricular tachycardia (all vts (fvt+vt)) when delivered in the right ventricle (rv) only versus both ventricles (biv) resulting in a 10 % difference in favour of biv atp secondary objectives: * compare efficacy of the first biv and rv atp (burst, 8 pulses, 88 %) to terminate fast ventricular tachycardia (fvt) * compare efficacy of the first biv and rv atp (burst, 8 pulses, 88 %) to terminate slow ventricular tachycardia (slow vt) * compare efficacy of biv and rv atp (all atp therapies) to terminate slow ventricular tachycardia (slow vt) * determine the rate of both fvt and vt episodes which are accelerated or degenerates into vf

Eligibility criteria:
inclusion criteria: * crt + icd indications (class i-iia) according to the guidelines * patients have been implanted with a medtronic marquis family icd capable of rv-atp or biv-atp * patients in chronic af who undergo a complete av ablation and that the complete av block is confirmed at phd exclusion criteria: * patient's life expectancy less than 1 year due to a non cardiac chronic disease * patient on heart transplant list which is expected in \< 1 year * patient's age less than 18 years * replacements and upgrades * epicardial lead * mechanical tricuspid valve * ventricular tachyarrhythmias associated with reversible causes * unwillingness or inability to provide written informed consent * enrollment in, or intention to participate in, another clinical study during the course of this study * inaccessibility for follow-up at the study center

Keywords: atp tachycardia crt-d
safety study of sgn-cd70a in cancer patients

Conditions: Renal Cell Carcinoma; Mantle-Cell Lymphoma; Diffuse, Large B-Cell, Lymphoma; Follicular Lymphoma, Grade 3

Summary: this study will examine the safety profile of sgn-cd70a. the study will test increasing doses of sgn-cd70a given every 3 weeks (or an alternate dosing schedule up to every 6 weeks) to small groups of patients. the goal is to find the highest dose of sgn-cd70a that can be given to patients without causing unacceptable side effects. the pharmacokinetics and antitumor activity of sgn-cd70a will also be evaluated.


Eligibility criteria:
inclusion criteria: * metastatic renal cell carcinoma, mantle cell lymphoma, or diffuse large b-cell lymphoma including grade 3b follicular lymphoma * relapsed, refractory, or progressive disease following at least 2 prior systemic therapies * confirmed positive cd70 expression on tumor tissue * eastern cooperative oncology group performance status 0 or 1 * adequate baseline hematologic, pulmonary, renal, and hepatic function * measurable disease exclusion criteria: * prior treatment with anti-cd70 directed therapy unless cd70 expression is confirmed on tumor tissue obtained after the treatment * patients \<100 days since prior allogeneic stem cell transplant * less than 4 weeks since prior treatment; or 2 weeks if patient experienced disease progression on the prior treatment

Keywords: renal cell carcinoma mantle-cell lymphoma diffuse, large b-cell, lymphoma follicular lymphoma, grade 3 antibody-drug conjugate cd70 antigen drug therapy
clinical validation of dystonianet deep learning platform for diagnosis of isolated dystonia

Conditions: Dystonia; Drug Induced Dystonia; Parkinson Disease; Essential Tremor; Dyskinesias; Myoclonus; Tic Disorders; Torticollis; Ulnar Nerve Entrapment; Temporomandibular Joint Disorders; Dysphonia

Summary: this research involves retrospective and prospective studies for clinical validation of a dystonianet deep learning platform for the diagnosis of isolated dystonia.

isolated dystonia is a movement disorder of unknown pathophysiology, which causes involuntary muscle contractions leading to abnormal, typically patterned, twisting movements and postures. a significant challenge in the clinical management of dystonia is due to the absence of a biomarker and associated 'gold' standard diagnostic test. currently, the diagnosis of dystonia is guided by clinical evaluations of its symptoms, which lead to a low agreement between clinicians and a high rate of diagnostic inaccuracies. it is estimated that only 5% of patients receive an accurate diagnosis at symptom onset, and the average diagnostic delay extends up to 10.1 years. this study will conduct retrospective and prospective studies to clinically validate the performance of dystonianet, a biomarker-based deep learning platform for the diagnosis of isolated dystonia. the retrospective studies will clinically validate the diagnostic performance of the dystonianet algorithm (1) in patients compared to healthy subjects (normative test), and (2) between patients with dystonia and other neurological and non-neurological conditions (differential test). the prospective randomized study will validate the performance of dystonianet algorithm for accurate, objective, and fast diagnosis of dystonia in the actual clinical setting. this research is expected to advance the dystonianet algorithm for dystonia diagnosis into its clinical use for increased accuracy of dystonia diagnosis. early detection and diagnosis of dystonia will enable its early therapy and improved prognosis, having an overall positive impact on healthcare and patients' quality of life.

Eligibility criteria:
inclusion criteria: 1. males and females of diverse racial and ethnic backgrounds, with age across the lifespan; 2. patients will have at least one of the forms of dystonia, including focal dystonia (e.g., laryngeal, cervical, oromandibular, blepharospasm, focal hand, musicians), segmental dystonia, or generalized dystonia; 3. patients will have other movement disorders (parkinson's disease, essential tremor, dyskinesia, myoclonus) and other non-neurological conditions (tic disorders, torticollis, ulnar nerve entrapments, temporomandibular disorders, dysphonia) that mimic dystonic symptoms. exclusion criteria: 1. patients who are incapable of giving informed consent; 2. patients who are unable to undergo brain mri due to the presence of certain tattoos and ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve) that cannot be removed or due to pregnancy or breastfeeding at the time of the study.
substitution of propofol by sevoflurane during pediatric cardiopulmonary bypass

Conditions: Metabolic Acidosis

Summary: propofol has been routinely used for general anesthesia during pediatric cardiopulmonary bypass at our institution without complications. however, propofol may cause propofol infusion syndrome (pris), a rare, but often fatal complication mainly defined by bradycardia with progress to asystolia. metabolic acidosis is regarded as an early warning sign of pris. due to the preconditioning effects of sevoflurane and its availability for cardiopulmonary bypass, propofol has recently been substituted by sevoflurane during pediatric cardiopulmonary bypass at our institution. in this study the effect of substituting propofol by sevoflurane on metabolic acidosis and outcome are examined.

in this retrospective and partially prospective observational study the charts of 200 children anesthetised for pediatric heart surgery are analysed since september 2007. 100 children received propofol and up to now 80 children received sevoflurane during cardiopulmonary bypass. blood gas analysis, laboratory results and vital parameters are compared before and after cardiopulmonary bypass for each group. duration of intensive care treatment and time to dismission from hospital are compared between groups. changes relative to baseline are analysed by paired t-test with correction for multiple testing. differences between groups are analysed by unpaired t-test with correction for multiple testing

Eligibility criteria:
inclusion criteria: * children scheduled for heart surgery including cardiopulmonary bypass
probiotic supplementation during cytotoxic chemotherapy for solid tumor malignancies

Conditions: Solid Tumor, Adult; Cytotoxicity

Summary: this is a pilot single-blind placebo-controlled randomized trial to establish experimental feasibility. we plan on enrolling a pilot cohort of 40 patients, with up to 5 patients in treatment phase 0 and the remaining in treatment phase i. during phase i, the remaining participants will be assigned to either treatment or control group using dynamic block randomization balancing on sex, age group, and disease histology.


Eligibility criteria:
inclusion criteria: * adults ≥18 years old * diagnosis of stage iii colon cancer * undergoing chemotherapeutic treatment within the mhfv or mvahc medical systems. exclusion criteria: * allergy or sensitivity to probiotic supplementation * diagnosis/history of: non-colon gi cancer or chronic gi-related disease or disorders such as gastric ulcer, irritable bowel syndrome, inflammatory bowel disease, or intestinal malabsorption syndrome cognitive impairment, such as dementia, or developmental disorder that would affect ability to give consent or comply with study procedures * current treatment of cancer other than non-melanoma skin cancer, including metastases and recurrences * current participation in another interventional study of medication(s) * major changes in eating habits within the past 3 months, such as stopping or starting a restricted diet * bmi ≥40 kg/m2 or ≤17 kg/m2 * unexpected change in weight of ˃4.5 kg within the past 6 months
long-term immunogenicity of the norovirus gi.1/gii.4 bivalent virus-like particle (vlp) vaccine (nov vaccine) in adults

Conditions: Healthy Volunteers; Norovirus

Summary: the purpose of this study is to evaluate descriptively the long-term immunogenicity of at least 1 nov vaccine administration.

results prepared and posted by takeda on behalf of hillevax, the ind holder. the drug being tested in this study is called nov vaccine. nov vaccine is being tested for protection against acute gastroenteritis (age) due to norovirus. the study will enroll maximum of approximately 575 participants. participants who previously received nov vaccine in studies nor-107, nor-210 and nor-204 will be enrolled. participants from study nor-107 will enter the study at the time of their 3rd year post-primary vaccination, and from studies nor-210 and nor-204, at their 2nd year post-primary vaccination. the duration of participation in the study will be different for each participant. this multi-center trial will be conducted in belgium and the united states. the overall time to participate in this study is maximum 5 years after primary nov vaccination. participants will have a maximum of 4 visits over 3 years

Eligibility criteria:
inclusion criteria: 1. male and female participants who previously received at least 1 dose of nov vaccine in trials nor-107 (nct02038907), nor-210 (nct02475278) and nor-204 (nct02661490), have baseline and post-vaccination data, and completed the primary vaccination trial protocol as initially described. exclusion criteria: 1. participation in any clinical trial is allowed, on condition that no investigational product is administered within 30 days prior to blood sampling. 2. in the opinion of the investigator, the participant is not medically eligible to provide blood specimens. 3. individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the trial.

Keywords: drug therapy
gemcitabine, oxaliplatin and radiation therapy in pancreatic cancer

Conditions: Pancreatic Neoplasms

Summary: this study will examine a proposed research treatment which evaluates the addition of oxaliplatin, a chemotherapy agent, to gemcitabine, another chemotherapy agent, and radiation therapy for the treatment of patients with pancreatic cancer. the researchers have already done studies using gemcitabine and radiation therapy together. they want to build on the information they have from this previous research. the researchers believe that the combination chemotherapy with radiation is worth investigating to treat pancreatic cancer. they will use this study to determine what type of side effects occur with this treatment and to assess how effective the treatment is at controlling the cancer.


Eligibility criteria:
inclusion criteria: * patients must have cytologic or histologic confirmation of carcinoma arising in the pancreas. * patients may have any stage of pancreatic cancer but if metastatic, systemic disease burden should be asymptomatic and small in volume. * determination of resectability must be made prior to registration. * patients must have an estimated life expectancy of at least 12 weeks and a zubrod performance status of \< = 2. * patients must have adequate organ function defined as follows: absolute neutrophil count of \> = 1500/mm3, platelets \> = 100,000/mm3, serum cr \< = 1.5 mg/dl, bilirubin \< 3.0 mg/dl, with relief of biliary obstruction if present (ptc tube or endobiliary stent). * patients must be free of other active systemic malignancy, ongoing infection, including hiv infection, or any other serious uncontrolled, concomitant systemic disorders or psychiatric condition that would interfere with the safe delivery of protocol therapy. * patients of reproductive potential must have agreed to use an effective contraceptive method during participation in this trial and for 6 months after trial. * patient must be aware of the investigational nature of the therapy and provide written informed consent. exclusion criteria: * patients with neuroendocrine tumors are excluded. * patients must have no history of previous chemotherapy for pancreatic cancer or any abdominal radiation therapy. * patient must not have used any investigational agent in the month before enrollment into the study.

Keywords: drug therapy radiotherapy clinical trial